Treatment for patients with indolent and mantle cell lymphoma-1

摘要

Mathias Rummel and colleagues (April 6, p 1203) report that median progression-free survival for patients with indolent lymphoma and mantle cell lymphoma was significantly improved with bendamustine plus rituximab compared with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) plus rituximab (R-CHOP). Furthermore, bendamustine plus rituximab was associated with fewer serious adverse events than was R-CHOP. However, several issues warrant further consideration.